High Testosterone Symptoms in Women: Drugs That Cause or Treat It

What Does High Testosterone Actually Feel Like in Women?

High testosterone in women produces a recognizable cluster of signs that span the skin, hair, reproductive system, and metabolism. Symptoms appear because androgen receptors sit in hair follicles, sebaceous glands, the uterus, and adipose tissue, so excess testosterone hits many organs at once.

Skin and Hair Changes

Acne is often the first complaint. Unlike the comedonal breakouts of adolescence, androgen-driven acne tends to appear along the jawline, chin, and neck in adult women. A 2021 analysis in the Journal of the American Academy of Dermatology found that women with confirmed hyperandrogenism had a 3.5-fold higher rate of persistent adult acne compared with age-matched controls [1].

Hirsutism, meaning terminal (coarse, pigmented) hair growth in a male-type distribution on the face, chest, abdomen, and inner thighs, affects roughly 70 to 80 percent of women with PCOS [2]. The modified Ferriman-Gallwey (mFG) score quantifies severity on a 0 to 36 scale; a score above 4 to 6 is considered abnormal in most populations [3].

Scalp hair thinning (female androgenetic alopecia) follows a diffuse pattern over the crown rather than the receding-hairline pattern seen in men.

Menstrual and Reproductive Symptoms

Elevated androgens suppress the normal LH surge and impair follicle maturation, producing oligomenorrhea (cycles longer than 35 days) or amenorrhea. Women may also notice reduced fertility. Clitoral enlargement and deepening of the voice signal more severe androgen excess and should prompt rapid evaluation for a tumor.

Metabolic Effects

Insulin resistance co-occurs with hyperandrogenism in approximately 50 to 70 percent of women with PCOS, according to a large cohort study published in Diabetes Care (N=1,127) [4]. Visceral fat accumulation, dyslipidemia (low HDL, elevated triglycerides), and pre-diabetes are all more common in this population than in age-matched women with normal androgen levels.

What Causes High Testosterone in Women?

Testosterone excess originates either from overproduction (ovaries, adrenal glands), reduced clearance, or an external source such as medication. Identifying the source matters because treatments differ substantially.

Polycystic Ovary Syndrome

PCOS is the dominant cause, accounting for 70 to 80 percent of hyperandrogenism cases in reproductive-age women [2]. The 2018 International Evidence-Based Guideline for the Assessment and Management of PCOS states: "Biochemical hyperandrogenism, specifically elevated free or total testosterone or elevated free androgen index, is the most reliable biochemical marker of PCOS" [5].

PCOS testosterone elevation typically ranges from 70 to 150 ng/dL total, with free testosterone disproportionately elevated because sex hormone-binding globulin (SHBG) is suppressed by insulin.

Adrenal Causes

Congenital adrenal hyperplasia (CAH), particularly the non-classic (late-onset) form caused by 21-hydroxylase deficiency, produces DHEA-S and androstenedione excess that peripheral tissues convert to testosterone. Non-classic CAH affects roughly 1 in 100 to 1 in 1,000 women of Ashkenazi Jewish, Hispanic, or Mediterranean ancestry [6].

Cushing syndrome (cortisol and androgen co-excess) and adrenocortical carcinoma are rarer but must be excluded when DHEA-S exceeds 700 mcg/dL.

Androgen-Secreting Tumors

Ovarian and adrenal tumors secreting testosterone are rare, representing fewer than 1 percent of hyperandrogenism cases. The clinical red flag is rapid-onset virilization (voice change, clitoromegaly, temporal balding developing over weeks to months) combined with total testosterone above 150 to 200 ng/dL. Transvaginal ultrasound and adrenal CT are first-line imaging in this context [7].

Other Medical Causes

Hypothyroidism lowers SHBG, raising free testosterone even when total levels are normal. Hyperprolactinemia stimulates adrenal androgen output. Severe insulin resistance syndromes (HAIRAN syndrome, Type A insulin resistance) can drive testosterone to dramatically elevated levels independent of PCOS.

Drugs That Raise Testosterone in Women

Several prescribed and non-prescribed compounds increase androgen levels as their primary mechanism or as an unintended side effect.

Anabolic-Androgenic Steroids

Exogenous anabolic steroids (nandrolone, stanozolol, oxandrolone) directly bind androgen receptors and suppress the hypothalamic-pituitary axis, raising circulating androgens. Use among women athletes has risen; a 2020 survey cited by the World Anti-Doping Agency estimated that 1.3 to 1.6 percent of competitive female athletes report lifetime AAS use [8]. Virilization, clitoral enlargement, and permanent voice change can occur within weeks of high-dose use.

Danazol

Danazol is a synthetic androgen once widely used for endometriosis. It suppresses SHBG, raises free testosterone, and directly activates androgen receptors. The FDA label for danazol lists virilization as an expected dose-dependent effect [9]. Lower-dose formulations (50 to 100 mg/day) are still used for hereditary angioedema in women; androgenic side effects are dose-related.

Valproic Acid (Valproate)

A 2011 prospective study published in Epilepsia (N=238) found that women with epilepsy taking valproate had significantly higher testosterone and lower SHBG than those taking lamotrigine or carbamazepine, and had a higher prevalence of PCOS-like features [10]. The mechanism likely involves insulin resistance and direct stimulation of ovarian androgen synthesis.

Testosterone Therapy Itself

Prescribed testosterone (gels, pellets, injections) used in postmenopausal women for hypoactive sexual desire disorder can overshoot the target range. Levels above 150 ng/dL are associated with acne, hirsutism, and suppression of menstrual cycles in premenopausal women who are prescribed testosterone off-label.

Other Compounds to Know

Dehydroepiandrosterone (DHEA) supplements, sold over the counter in the United States, are converted peripherally to testosterone and estradiol. A randomized trial in JAMA (N=280) showed that 50 mg/day DHEA raised total testosterone by a mean of 68 percent above baseline in postmenopausal women [11]. Tibolone, a synthetic steroid used in some countries for menopausal HRT, has androgenic metabolites that raise free testosterone and may worsen acne or hirsutism.

How Is High Testosterone Diagnosed in Women?

Diagnosis requires combining symptom assessment, validated clinical scoring, and targeted laboratory work. A single lab value without clinical context is insufficient.

Laboratory Evaluation

The Endocrine Society recommends measuring total testosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS) rather than immunoassay in women, because immunoassays perform poorly at low concentrations [12]. Free testosterone calculated from total testosterone, SHBG, and albumin using the Vermeulen equation is the most clinically useful single number.

A reasonable initial panel includes:

• Total testosterone (LC-MS/MS preferred)
• Free testosterone (calculated or equilibrium dialysis)
• SHBG
• DHEA-S (to screen for adrenal contribution)
• LH and FSH (ratio above 2 to 3 suggests PCOS)
• Prolactin
• 17-hydroxyprogesterone (early-morning, follicular phase; screens for non-classic CAH)
• Fasting glucose and insulin (to assess insulin resistance)

Labs drawn in the early follicular phase (days 2 to 5 of the cycle) give the most reproducible results.

Imaging

Pelvic ultrasound remains a diagnostic criterion for PCOS under the revised Rotterdam criteria (2003, updated 2018), with polycystic ovarian morphology defined as 20 or more follicles per ovary or ovarian volume above 10 mL [5]. Adrenal CT is reserved for cases where DHEA-S exceeds 700 mcg/dL or testosterone exceeds 150 ng/dL and an adrenal source is suspected.

Drugs and Treatments That Lower Testosterone in Women

Treatment selection depends on whether the goal is to suppress symptoms, restore fertility, or treat an underlying cause.

Combined Oral Contraceptive Pills

Combined oral contraceptives (COCs) lower free testosterone through two mechanisms: they suppress LH-driven ovarian androgen production, and their estrogen component raises SHBG, binding more circulating testosterone. The 2018 PCOS guideline identifies COCs as first-line pharmacotherapy for menstrual irregularity and hirsutism when fertility is not desired [5].

Formulations containing progestins with lower androgenic activity (desogestrel, norgestimate, drospirenone) are preferred. Drospirenone has mild anti-mineralocorticoid and anti-androgenic properties and is a component of Yasmin (ethinyl estradiol 30 mcg / drospirenone 3 mg) and Yaz (ethinyl estradiol 20 mcg / drospirenone 3 mg), both FDA-approved for acne in women [13].

Spironolactone

Spironolactone is an aldosterone antagonist with potent anti-androgenic activity. It blocks the androgen receptor, inhibits 5-alpha reductase in hair follicles, and modestly reduces adrenal androgen production. The standard dose for hirsutism and acne is 50 to 200 mg/day orally [14].

A Cochrane systematic review of 32 randomized trials concluded that spironolactone at 100 mg/day produced a statistically significant reduction in the mFG hirsutism score compared with placebo, with the clearest effect evident at 6 months [15]. Because spironolactone is teratogenic (risk of feminization of a male fetus), reliable contraception is required during use.

Metformin

Metformin lowers insulin and, secondarily, ovarian androgen production. A meta-analysis in Human Reproduction (22 trials, N=1,335) found that metformin 1,500 to 2,550 mg/day reduced total testosterone by a mean of 0.40 nmol/L (11.5 ng/dL) in women with PCOS [16]. Metformin is particularly appropriate when insulin resistance, impaired fasting glucose, or a high risk of type 2 diabetes is present alongside hyperandrogenism.

GnRH Agonists

Leuprolide (Lupron) and nafarelin act by downregulating pituitary GnRH receptors after an initial flare, suppressing LH and FSH and thereby switching off ovarian testosterone production. They reduce testosterone to postmenopausal or castrate levels within 3 to 4 weeks. GnRH agonists are generally reserved for severe hyperandrogenism that does not respond to COCs and spironolactone, or for cases where an androgen-secreting ovarian source is being managed medically before surgery [7]. Long-term use requires add-back estrogen to prevent bone loss.

Finasteride and Dutasteride

Finasteride 2.5 to 5 mg/day and dutasteride 0.5 mg/day block 5-alpha reductase, preventing conversion of testosterone to its more potent metabolite dihydrotestosterone (DHT) in peripheral tissues. They are sometimes prescribed off-label for hirsutism and female androgenetic alopecia when spironolactone is not tolerated. Both are teratogenic; contraception is mandatory. A 2020 randomized trial in JAMA Dermatology (N=140) found dutasteride 0.5 mg non-inferior to finasteride 5 mg for female pattern hair loss at 24 weeks [17].

Treating the Underlying Cause

When an androgen-secreting tumor is identified, surgical resection is the primary treatment. For non-classic CAH, low-dose glucocorticoids (hydrocortisone 5 to 7.5 mg twice daily or prednisone 2.5 to 5 mg/day) suppress excess adrenal androgen production.

Hypothyroidism responds to levothyroxine, which normalizes SHBG and reduces free testosterone without any direct anti-androgen action. Stopping or substituting valproate, when clinically feasible, can reverse valproate-associated hyperandrogenism within 3 to 6 months.

When Should You Be Worried? Clinical Red Flags

Most high-testosterone states in women are benign and manageable. A smaller subset signal serious pathology requiring prompt action.

See a provider within 1 to 2 weeks if:

• Total testosterone exceeds 150 ng/dL on a repeat confirmatory test
• DHEA-S exceeds 700 mcg/dL
• Symptoms developed rapidly (weeks, not months or years)
• Voice deepening, clitoromegaly, or temporal balding is present
• 17-hydroxyprogesterone (early-morning follicular) exceeds 10 ng/mL, suggesting classic CAH

Routine outpatient workup is sufficient if:

• Total testosterone is 70 to 150 ng/dL with a multi-year symptom history
• Clinical picture fits PCOS (irregular cycles, polycystic ovaries, no virilization)
• 17-hydroxyprogesterone is below 2 ng/mL

A 2019 review in The Lancet Diabetes and Endocrinology concluded: "The combination of total testosterone above 5.2 nmol/L (150 ng/dL) and rapid symptom onset should be considered indicative of a secretory tumor until proved otherwise" [7].

Lifestyle Changes That Complement Drug Treatment

Medication works faster when lifestyle factors are addressed in parallel. Weight loss of 5 to 10 percent of body weight in overweight women with PCOS reduces fasting insulin by approximately 30 percent and lowers free testosterone by a clinically meaningful margin [5]. A 2019 randomized controlled trial published in Diabetes Care (N=149) showed that a 5 percent weight reduction achieved via a structured diet lowered free androgen index by 21 percent at 6 months without any pharmacological intervention [18].

Resistance training three times per week improves insulin sensitivity independently of weight change. Limiting ultra-processed foods and refined carbohydrates reduces postprandial insulin spikes that drive ovarian androgen synthesis. These changes do not replace medication for moderate to severe hyperandrogenism but reduce the dose needed and improve long-term outcomes.

Monitoring Treatment Progress

Lab Follow-Up Schedule

Repeat total testosterone, free testosterone, and SHBG at 3 months after starting any anti-androgen regimen. For spironolactone, check serum potassium and blood pressure at 4 to 6 weeks because the drug's mineralocorticoid-blocking properties can raise potassium, particularly in women with renal impairment.

Hirsutism lags behind biochemical improvement because a hair follicle cycle lasts 6 months. Clinicians should counsel women that mFG score reductions are not detectable before 6 months of consistent therapy, and maximal response takes 12 months.

Repeat fasting lipids and glucose at 6 months in women who also have metabolic syndrome, as controlling androgen excess alone improves both without additional lipid-lowering therapy in some patients.

Adjusting Therapy

If testosterone remains above 80 ng/dL after 3 months on a COC, adding spironolactone 50 mg/day and titrating by 50 mg every 4 to 6 weeks to a maximum of 200 mg/day is a standard escalation step. The combination of a COC with spironolactone produces a greater SHBG increase and anti-androgenic receptor blockade than either agent alone [14].

For women who want pregnancy, neither COC nor spironolactone is appropriate. Metformin or clomiphene citrate (for ovulation induction) are the preferred options, with letrozole now preferred over clomiphene for ovulation induction in PCOS per the 2018 PCOS guideline [5].